Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment

Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice

(2019) Lucie Bartova et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study

(2018) Markus Dold et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

International trends in antipsychotic use: A study in 16 countries, 2005–2014

(2017) Óskar Hálfdánarson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines

(2017) Michael Bauer et al.   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Administration of ketamine for unipolar and bipolar depression

(2017) Christoph Kraus et al.   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study

(2016) Markus Dold et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Evidence-based pharmacotherapy of treatment-resistant unipolar depression

(2016) Markus Dold et al.   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis

(2015) Xinyu Zhou et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Factors contributing to the increasing placebo response in antidepressant trials

(2015) Siegfried Kasper et al.   World Psychiatry

A Model of Placebo Response in Antidepressant Clinical Trials

(2013) Bret R. Rutherford et al.   AMERICAN JOURNAL OF PSYCHIATRY

Rational site-directed pharmacotherapy for major depressive disorder

(2013) Pierre Blier   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program

(2011) A. Konstantinidis et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression

(2011) Daniel Souery et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Does Inclusion of a Placebo Arm Influence Response to Active Antidepressant Treatment in Randomized Controlled Trials?

(2010) Mark Sinyor et al.   JOURNAL OF CLINICAL PSYCHIATRY

Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials

(2009) J. Craig Nelson et al.   AMERICAN JOURNAL OF PSYCHIATRY

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

(2009) Stuart A. Montgomery et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD

(2008) George I. Papakostas et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches

(2007) George I. Papakostas et al.   BIOLOGICAL PSYCHIATRY